He is the author of 80 peer-review publications that include more than 15 reviews with more than 3000 citations. His scientific interests include cancer, cell cycle, CDK inhibitors, oncogenic transcription factors FOXM1 and c-Myc, and mechanisms of action of anticancer drugs. Recently his lab discovered that FOXM1, which is strongly overexpressed in a human cancer, is a novel major target for proteasome inhibitors. He received his funding from NIH, DOD and private companies/foundations.